# Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE

Study · id `cardio:ct-nct05995600` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05995600](<https://clinicaltrials.gov/study/NCT05995600>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05995600

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05995600. Randomized; single masking; primary purpose prevention. Start 2024-02-20 (actual); primary completion 2029-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05995600, source copy `cardio:ctgov-nct05995600-2026-09-11`, retrieved 2026-10-26)
- Started: 2024-02-20 (actual) (ClinicalTrials.gov record NCT05995600, source copy `cardio:ctgov-nct05995600-2026-09-11`, retrieved 2026-10-26)
- Primary completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT05995600, source copy `cardio:ctgov-nct05995600-2026-09-11`, retrieved 2026-10-26)
- Completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT05995600, source copy `cardio:ctgov-nct05995600-2026-09-11`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05995600, source copy `cardio:ctgov-nct05995600-2026-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05995600-2026-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
- Acronym: APS-STROKE
- Condition: Antiphospholipid Syndrome
- Condition: Ischemic Stroke
- Condition: Transient Ischemic Attack
- Condition: Cerebrovascular Disease
- Condition: Cardiovascular Diseases
- Condition: Major Bleed
- Intervention (Drug): Antiplatelet Drug
- Intervention (Drug): Warfarin
- Lead sponsor: Seoul National University Hospital
- Lead sponsor class: OTHER
- Collaborator: Samjin Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Transient ischemic attack (mini-stroke) (`cardio:transient-ischemic-attack`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Seoul National University Hospital (`cardio:org-seoul-national-university-hospital`)
- Registry lists this organization as a collaborator: Samjin Pharmaceutical Co., Ltd. (`cardio:org-samjin-pharmaceutical-co-ltd`)

## Provenance

Content hash: 9594edc5685336a111cb05c5d833082abca65e812de0e912c612efa5ff33d20d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
